The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 347:1721-1722 November 21, 2002 Number 21
NextNext

Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
by Liang, T. J.
-Related Article
by Yang, H.-I
-PubMed Citation
To the Editor: Yang et al. (July 18 issue)1 report that the detection of hepatitis B e antigen (HBeAg) at a single point in time during the course of chronic hepatitis B predicts the development of hepatocellular carcinoma. As noted in the article and the accompanying editorial,2 there are no hints of the direct involvement of HBeAg in the mutagenicity in the liver. On the other hand, HBeAg represents a surrogate marker of viral replication and necroinflammatory activity. The authors discuss both direct mechanisms of carcinogenicity (hepatitis B x antigen [HBxAg]–related effects) and indirect mechanisms of carcinogenicity (chronic hepatic inflammation . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.